244 related articles for article (PubMed ID: 9129786)
1. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
[No Abstract] [Full Text] [Related]
2. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Silver H; Geraisy N
Biol Psychiatry; 1995 Sep; 38(6):413-5. PubMed ID: 8547463
[No Abstract] [Full Text] [Related]
3. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
4. [Exacerbation of catatonic symptoms in neuroleptic therapy].
Bräunig P; Krüger S; Höffler J
Nervenarzt; 1995 May; 66(5):379-82. PubMed ID: 7609820
[TBL] [Abstract][Full Text] [Related]
5. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
[TBL] [Abstract][Full Text] [Related]
6. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
7. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
8. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
[TBL] [Abstract][Full Text] [Related]
9. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
10. New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N
Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161
[No Abstract] [Full Text] [Related]
11. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
[No Abstract] [Full Text] [Related]
12. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
13. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
14. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Allen RM
Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548
[TBL] [Abstract][Full Text] [Related]
15. Negative symptoms: relationship to other schizophrenic symptom classes.
McKenna PJ; Lund CE; Mortimer AM
Br J Psychiatry Suppl; 1989 Nov; (7):104-7. PubMed ID: 2619978
[No Abstract] [Full Text] [Related]
16. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
McEvoy JP; McCue M; Freter S
Clin Ther; 1987; 9(4):429-33. PubMed ID: 2886223
[TBL] [Abstract][Full Text] [Related]
17. Clinical findings. Abnormalities of the mental state and movement disorder and their correlates.
Johnstone EC; Owens DG; Frith CD; Leary J
Br J Psychiatry Suppl; 1991 Oct; (13):21-5, 44-6. PubMed ID: 1688117
[No Abstract] [Full Text] [Related]
18. The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
Gerbaldo H; Demisch L; Lehmann CO; Bochnik J
Pharmacopsychiatry; 1988 Nov; 21(6):387-8. PubMed ID: 2907646
[No Abstract] [Full Text] [Related]
19. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
[TBL] [Abstract][Full Text] [Related]
20. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
